TRANSTHERA's core product, Tiengoti, publishes exploratory clinical results

TRANSTHERA-B (02617.HK) announced that recently, the exploratory Phase 2 results of its core product, Tiengotine, for cholangiocarcinoma conducted in the United States were published in The Lancet Gastroenterology & Hepatology. Tiengotine can overcome acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma and has shown anti-tumor activity in other cholangiocarcinoma patients with FGFR gene alterations.

In this Phase 2, open-label, multicenter study, eligible cholangiocarcinoma patients included those with FGFR2 fusion and primary or acquired resistance to FGFR inhibitors, patients with other FGFR gene alterations, and FGFR wild-type patients